On his first day in office, President Trump rescinded Executive Order 14087, which sought to implement programs aimed at reducing prescription drug prices. This included a pilot program offering generic medications for a $2 copay to Medicare Part D recipients. Critics point out that this decision suggests a continued lack of focus on addressing affordability in healthcare. Furthermore, uncertainties linger about Trump's plans regarding government negotiation of drug prices under the Inflation Reduction Act, raising concerns among advocacy groups and public health experts about the future of drug pricing strategies.
This act is a good indication of how Trump will approach lower drug prices, highlighting a lack of focus on affordability and access to medications.
The big question, which Trump hasn't addressed yet, is what he'll do with government negotiation of drug prices under the Inflation Reduction Act.
Trump’s decision to rescind the executive order halts critical pilot programs aimed at reducing prescription drug costs for Americans, impacting Medicare Part D recipients.
In the wake of the repeal, many uncertainties remain about future drug pricing strategies and their effects on patients and the healthcare system.
Collection
[
|
...
]